Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colistin-conjugated selenium nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Baghdad
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
01
Overview
**Colistin-conjugated selenium nanoparticles** are an experimental preclinical nanotherapeutic consisting of selenium nanoparticles functionalized with the polymyxin antibiotic colistin. In an in vitro 2025 study, the construct showed enhanced activity against multidrug-resistant *Pseudomonas aeruginosa*, including reduced *mexY* efflux-pump gene expression, and greater antifungal activity than unconjugated selenium nanoparticles against *Candida albicans*, *Candida glabrata*, and *Candida krusei*. It also produced dose-dependent cytotoxicity in MCF-7 human breast cancer cells, associated with oxidative stress and apoptosis. The construct has not been reported as a clinically developed, marketed, or approved medicinal product.
- Other names
- Col-SeNPs
02
Targets
MexY (MexY efflux pump subunit)
Beyond the preview
Go deeper on colistin-conjugated selenium nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colistin-conjugated selenium nanoparticles.